First-in-Human, Multicenter, Phase I Dose-Escalation and Expansion Study of Anti-Mesothelin Antibody–Drug Conjugate Anetumab Ravtansine in Advanced or Metastatic Solid Tumors

PURPOSE: This phase I study, which to our knowledge is the first-in-human study of this kind, investigates the safety, tolerability, pharmacokinetics, and clinical activity of anetumab ravtansine, an antibody–drug conjugate of anti-mesothelin antibody linked to maytansinoid DM4, in patients with adv...

Descripción completa

Detalles Bibliográficos
Autores principales: Hassan, Raffit, Blumenschein, George R., Moore, Kathleen N., Santin, Alessandro D., Kindler, Hedy L., Nemunaitis, John J., Seward, Shelly M., Thomas, Anish, Kim, Stella K., Rajagopalan, Prabhu, Walter, Annette O., Laurent, Dirk, Childs, Barrett H., Sarapa, Nenad, Elbi, Cem, Bendell, Johanna C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Clinical Oncology 2020
Materias:
ORIGINAL REPORTS
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7255978/
https://www.ncbi.nlm.nih.gov/pubmed/32213105
http://dx.doi.org/10.1200/JCO.19.02085

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7255978/
https://www.ncbi.nlm.nih.gov/pubmed/32213105
http://dx.doi.org/10.1200/JCO.19.02085

Ejemplares similares